IP Library Patent Application 17889633
Patent Application
App. No. 17/889,633

HIGH FREQUENCY ELECTROMAGNETIC STIMULATION FOR MODULATING CELLS, INCLUDING SPONTANEOUSLY ACTIVE AND QUIESCENT CELLS, AND ASSOCIATED SYSTEMS AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/889,633
Abstract

Electromagnetic stimulation for treating diseases, conditions associated with diseases and/or inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, high-frequency stimulation in the range of from about 1.5 kHz to about 100 kHz may be applied to a patient's target tissue region to treat the disease, associated condition and/or to inhibit pain. Electrical stimulation in accordance with similar parameters can directly affect a cellular membrane, such as a neuron and in particular, a spontaneously active neuron and/or a quiescent neuron.

Claims (33)

1 - 16 . (canceled)

17 . A method for treating a patient, comprising:

screening the patient for responsiveness to a high frequency electrical therapy by delivering a test signal to the patient, the test signal having a frequency in a range from 1.5 kHz to 100 kHz; and

measuring an evoked potential from a C-fiber; and

if the evoked potential is below a threshold level, applying a therapeutic signal to the patient, the therapeutic signal having a frequency in a range from 1.5 kHz to 100 kHz.

18 . The method of claim 17 wherein an individual neuron of the patient includes a cell body, an axon, and a dendrite, and wherein applying the therapeutic signal to the patient includes preferentially applying the therapeutic signal to the cell body.

19 . The method of claim 17 wherein applying the therapeutic signal to the patient includes applying the therapeutic signal to a region of the patient that includes C-type fibers and A-type fibers, and wherein the method further comprises preferentially directing the therapeutic signal to the C-type fibers.

20 . The method of claim 17 wherein applying the therapeutic signal includes inhibiting neuronal activity of quiescent neurons.

21 . The method of claim 17 wherein applying the therapeutic signal includes inhibiting neuronal activity of spontaneously active neurons.

22 . The method of claim 17 wherein screening the patient further comprises applying a stimulus to the patient while simultaneously delivering the test signal, and wherein the evoked potential is in response to the stimulus.

23 . The method of claim 17 wherein the threshold level is equivalent to an evoked potential in the absence of the test signal.

24 . The method of claim 17 wherein applying the therapeutic signal to the patient includes delivering the therapeutic signal to the patient's spinal cord region.

25 . The method of claim 17 wherein applying the therapeutic signal to the patient includes delivering the therapeutic signal to a peripheral nerve.

26 . The method of claim 17 wherein applying the therapeutic signal to the patient at least partially alleviates patient pain.

27 . The method of claim 17 wherein the therapeutic signal has a pulse width in a pulse width range of from about 10 microseconds to about 333 microseconds, and an amplitude in an amplitude range of from about 0.1 mA to about 20 mA.

28 . The method of claim 17 wherein the frequency range of the therapeutic signal is from about 3 kHz to about 20 kHz.

29 . A method for treating a patient, comprising:

screening the patient for responsiveness to a high frequency electrical therapy by:

delivering a test signal to the patient, the test signal having a frequency in a range from 1.5 kHz to 100 kHz, and

measuring an evoked potential from a C-fiber; and

if the evoked potential is below a threshold level, programming a signal generator to deliver a therapeutic signal to the patient, the therapeutic signal having a frequency in a range from 1.5 kHz to 100 kHz.

30 . The method of claim 29 wherein the threshold level is equivalent to an evoked potential in the absence of the test signal.

31 . The method of claim 29 wherein programming the signal generator to deliver the therapeutic signal includes programming the signal generator to deliver the therapeutic signal via an electrode positioned to preferentially direct the therapeutic signal to C-type fibers of the patient.

32 . A method for treating a patient, comprising:

screening the patient for responsiveness to spinal cord stimulation therapy by:

delivering a test signal to the patient, the test signal having a frequency in a range from 1.5 kHz to 100 kHz,

while delivering the test signal, applying a stimulus to the patient, and

measuring a response to the stimulus from a C-fiber of the patient; and

if the response to the stimulus is below a threshold level, programming a signal generator to deliver an electrical therapy signal to a spinal cord region of the patient via an implanted electrode, the electrical therapy signal having a frequency in a frequency range from 1.5 kHz to 100 kHz.

33 . The method of claim 32 wherein screening the patient is done in response to the patient having pain, and wherein the electrical therapy signal at last partially alleviates the patient pain.

34 . The method of claim 32 wherein the threshold level is equivalent to a response to the stimulus in the absence of the test signal.

35 . The method of claim 32 wherein the implanted electrode is positioned to preferentially direct the electrical therapy signal to C-type fibers at the spinal cord region.

36 . The method of claim 32 wherein the therapeutic signal has a pulse width in a pulse width range of from about 10 microseconds to about 333 microseconds, and an amplitude in an amplitude range of from about 0.1 mA to about 20 mA.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2023
From: LEE, DONGCHUL
To: NEVRO CORP.
Reel/Frame 062802/0129 →